{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T04:11:16Z","timestamp":1729138276316,"version":"3.27.0"},"reference-count":20,"publisher":"Baishideng Publishing Group Inc.","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Psychiatry"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Imipenem is a highly effective carbapenem antibiotic, which is widely used in the treatment of many serious bacterial infections. At the same time, it can also cause some adverse reactions, mental abnormalities are the most concerned central nervous system adverse reactions. Different patients respond differently to imipenem, and the effect of imipenem on psychiatric disorders is unclear. Therefore, meta-analysis summarizing the results of multiple previous studies can provide stronger evidence support for clinical guidelines to guide clinical rational use of imipenem to minimize risks.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To systematically review the effects of imipenem on mental-health disorders.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>Method in Cochrane Library, Web of science, PubMed, ProQuest, and China\u2019s biomedical literature databases Wanfang, Weipu and China HowNet, the related literatures about the controlled trials of imipenem-induced mental disorders from the establishment of the database to May 2024 were searched; the included literatures were analyzed using RevMan 5.4 software; and the heterogeneity among the studies was also discussed.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>After reviewing the literature published between 2003 and 2017, seven controlled trials with a total of 550 patients were included, with 273 and 277 patients in the control and experimental groups, respectively. The sample size of the study ranged from a minimum of 30 cases to a maximum of 61 cases. Patients in the experimental group were treated with imipenem while the control group was treated with conventional drugs. Meta-analysis showed that the incidence of mental disorders in the experimental group was higher than that in the control group (odds ratio = 3.66, 95% confidence interval: 1.11-12.11, P  = 0.030); however, there was no significant difference in the incidence of adverse reactions between the two groups (odds ratio = 0.05, 95% confidence interval: 0.00 to 0.10, P  = 0.060). Funnel diagrams showed that the scattered points of each study were symmetrical and distributed in an inverted funnel shape; therefore, there was no publication bias.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>Imipenem can cause mental disorders in patients. However, the low quality of the included literature may have affected the final results. Therefore, it is necessary to conduct a high-quality randomized controlled study with multiple samples to further confirm the mechanism of imipenem-induced mental disorders and provide effective guidance for clinical treatment.<\/jats:p>","DOI":"10.5498\/wjp.v14.i10.1583","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T05:12:48Z","timestamp":1729055568000},"page":"1583-1591","source":"Crossref","is-referenced-by-count":0,"title":["Mechanism of imipenem-induced mental disorder: A meta-analysis"],"prefix":"10.5498","volume":"14","author":[{"given":"Zhou-Hong","family":"Zhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan-Nan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Na","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"B1","unstructured":"Jin SP, Lan L, Li CJ. [Imine south\/west division of his ding adverse reactions summary of recent literature]. Zhongguo Yaowu Lanyong Fangzhi Zazhi 2014; 2"},{"key":"B2","unstructured":"Li P. [Clinical pharmacists participated in the treatment of epilepsy induced by imipenem cilastatin: a case report]. Zhongguo Xiandai Yaowu Yingyong 2015; 9"},{"key":"B3","unstructured":"Wen AP, Li DD, Bao XL. [Incidence and risk factors of central nervous system adverse reactions induced by imipenem\/Cilastatin in adult critically ill patients]. Zhongguo Yaowu Yingyong Yu Jiance 2019; 16"},{"key":"B4","unstructured":"Zhu ZD, Chen DQ, Wang LY, Wang WL. [Analysis of nervous system adverse reactions induced by imipenem\/Cilastatin in patients with heart failure and severe infection]. Zhongguo Xiandai Yaowu Yingyong 2008"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.16718\/j.1009-7708.2010.04.013"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002023"},{"key":"B7","unstructured":"Yang XD. [Effect of imipenem\/Cilastatin and norvancomycin in the treatment of patients with lower respiratory tract infection]. Zhongguo Chufangyao 2017; 100-101"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.11816\/cn.ni.2015-140420"},{"key":"B9","unstructured":"Chen MF. [Clinical analysis of imipenem-cilastatin in the treatment of 46 cases of severe infection]. Zhejiang Yixue 2010; 264-265"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3321\/j.issn:1005-4529.2005.09.032"},{"key":"B11","unstructured":"Liu Y, Liu XM. [Comparison of clinical efficacy and safety of meropenem in the treatment of severe pneumonia caused by extended-spectrum \u03b2 -lactamases producing bacteria]. Zhongguo Jijiu Yixue 2004"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3321\/j.issn:1005-4529.2003.04.027"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3321\/j.issn:1009-7708.2005.06.016"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14693"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01506-19"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2020.01.001"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2021.8469\/2021"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13796"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.16153\/j.1002-7777.2018.07.021"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa803"}],"container-title":["World Journal of Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2220-3206\/full\/v14\/i10\/1583.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2220-3206\/full\/v14\/i10\/1583.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T05:14:27Z","timestamp":1729055667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2220-3206\/full\/v14\/i10\/1583.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":20,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.5498\/wjp.v14.i10.1583","relation":{},"ISSN":["2220-3206"],"issn-type":[{"value":"2220-3206","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,19]]}}}